Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer ( 27T51-01)

Principal Investigator: Zsiros, Emese

Feasibility Study for ivWatch in prevention of extravasation of vesicants in an oncology setting

Principal Investigator: Storer, Andrew C

Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

Principal Investigator: Prasad, Dheerendra

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Principal Investigator: Dy, Grace K

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate…

Principal Investigator: Green, Steven D

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1…

Principal Investigator: Wang, Eunice S

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

Principal Investigator: Malek, Ehsan

Investigating The Effect of Testosterone Replacement Therapy Among Hypogonadal Men with Localized Prostate Cancer on Active Surveillance

Principal Investigator: Aly, Ahmed A

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer

Principal Investigator: Zsiros, Emese

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

(EA7222) A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Principal Investigator: Gupta, Ajay

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator: McLean, Karen

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Principal Investigator: George, Saby

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator: Wang, Eunice S

A FIRST-IN-HUMAN, PHASE 1, DOSE ESCALATION STUDY OF SGR-2921 AS MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Principal Investigator: Wang, Eunice S

A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)

Principal Investigator: Fountzilas, Christos

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/ or Metastatic Hepatocellular Carcinoma

Principal Investigator: Iyer, Renuka V

Phase II Randomized, Double Blind, Placebo-Controlled Trial of the Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers

Principal Investigator: Reid, Mary E

KOMEN-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(AALL2121) A Phase 2 study of revumenib (SNDX-5613) in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Principal Investigator: Mallhi, Kanwal

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM)

Principal Investigator: Hillengass, Jens

A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced endometrial cancer

Principal Investigator: Mager, Katherine

(EAY191-N5): A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

Principal Investigator: Levine, Ellis G

Phase II Study of Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Principal Investigator: Wang, Eunice S